Completely resected stage II~IIIA lung adenocarcinoma with EGFR-tyrosine kinase (TKI) sensitizing mutation (mEGFR) is treated with cisplatin-based adjuvant chemotherapy, which is similar to other non-small cell lung cancers irrespective to the EGFR mutation status. This evidence concerns the gene EGFR and lung adenocarcinoma.